Editorial
Cyclin D1 expression in KRAS mutant non-small cell lung cancer—old wine into new skins
Translational Lung Cancer Research
2020;
9
(6)
:2302-2304
.
(31 December 2020)
The gut microbiome and its interaction with health, disease, treatment response and toxicity in patients advanced cancer: focus on lung cancer and immunotherapy
Translational Lung Cancer Research
2020;
9
(6)
:2305-2307
.
(31 December 2020)
Radiomics signature for prediction of N2 disease: fascinating but still a long way to go for clinical application
Translational Lung Cancer Research
2020;
9
(6)
:2308-2310
.
(31 December 2020)
Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?
Translational Lung Cancer Research
2020;
9
(6)
:2311-2314
.
(31 December 2020)
Original Article
Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation
Translational Lung Cancer Research
2020;
9
(6)
:2315-2327
.
(31 December 2020)
Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease
Translational Lung Cancer Research
2020;
9
(6)
:2328-2336
.
(31 December 2020)
Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2
Translational Lung Cancer Research
2020;
9
(6)
:2337-2355
.
(31 December 2020)
Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma
Translational Lung Cancer Research
2020;
9
(6)
:2356-2366
.
(31 December 2020)
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy
Translational Lung Cancer Research
2020;
9
(6)
:2367-2367
.
(31 December 2020)
The feasibility of navigation bronchoscopy-guided pulmonary microcoil localization of small pulmonary nodules prior to thoracoscopic surgery
Translational Lung Cancer Research
2020;
9
(6)
:2380-2390
.
(31 December 2020)
Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(6)
:2391-2400
.
(31 December 2020)
Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study
Translational Lung Cancer Research
2020;
9
(6)
:2401-2410
.
(31 December 2020)
Hsa_circ_0006571 promotes spinal metastasis through sponging microRNA-138 to regulate sirtuin 1 expression in lung adenocarcinoma
Translational Lung Cancer Research
2020;
9
(6)
:2411-2427
.
(31 December 2020)
Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)
Translational Lung Cancer Research
2020;
9
(6)
:2428-2439
.
(31 December 2020)
The protective effects of granulocyte-macrophage colony-stimulating factor against radiation-induced lung injury
Translational Lung Cancer Research
2020;
9
(6)
:2440-2459
.
(31 December 2020)
Protocol
Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study
Translational Lung Cancer Research
2020;
9
(6)
:2460-2468
.
(31 December 2020)
Review Article
A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia
Translational Lung Cancer Research
2020;
9
(6)
:2469-2478
.
(31 December 2020)
A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player
Translational Lung Cancer Research
2020;
9
(6)
:2479-2493
.
(31 December 2020)
Case Report
Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
Translational Lung Cancer Research
2020;
9
(6)
:2494-2499
.
(31 December 2020)
A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(6)
:2500-2507
.
(31 December 2020)
Editorial Commentary
Comment on “EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach”
Translational Lung Cancer Research
2020;
9
(6)
:2508-2510
.
(31 December 2020)
Perspective of gene therapy with replication competent viruses
Translational Lung Cancer Research
2020;
9
(6)
:2511-2513
.
(31 December 2020)
Letter to the Editor
Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
Translational Lung Cancer Research
2020;
9
(6)
:2514-2517
.
(31 December 2020)
Editorial on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions1
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?
Translational Lung Cancer Research
2020;
9
(6)
:2518-2520
.
(31 December 2020)
Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions1
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
Translational Lung Cancer Research
2020;
9
(6)
:2521-2534
.
(31 December 2020)
How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?
Translational Lung Cancer Research
2020;
9
(6)
:2535-2544
.
(31 December 2020)
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
Translational Lung Cancer Research
2020;
9
(6)
:2545-2556
.
(31 December 2020)
The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
Translational Lung Cancer Research
2020;
9
(6)
:2557-2570
.
(31 December 2020)
Decade in review: a new era for RET-rearranged lung cancers
Translational Lung Cancer Research
2020;
9
(6)
:2571-2580
.
(31 December 2020)
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
Translational Lung Cancer Research
2020;
9
(6)
:2581-2598
.
(31 December 2020)
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
Translational Lung Cancer Research
2020;
9
(6)
:2599-2617
.
(31 December 2020)
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
Translational Lung Cancer Research
2020;
9
(6)
:2618-2628
.
(31 December 2020)
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Translational Lung Cancer Research
2020;
9
(6)
:2629-2644
.
(31 December 2020)
Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas
Translational Lung Cancer Research
2020;
9
(6)
:2645-2655
.
(31 December 2020)
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
Translational Lung Cancer Research
2020;
9
(6)
:2656-2673
.
(31 December 2020)
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
Translational Lung Cancer Research
2020;
9
(6)
:2674-2685
.
(31 December 2020)
How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease
Translational Lung Cancer Research
2020;
9
(6)
:2686-2695
.
(31 December 2020)
Consensus
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(6)
:2696-2715
.
(31 December 2020)
Disclosure:
1. The series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Silvia Novello and Francesco Passiglia served as the unpaid Guest Editors for the series.
